A Phase I/II Study of Weekly Topotecan and Gefitinib (Iressa) in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Gefitinib (Primary) ; Topotecan (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results assessing efficacy, safety, and toxicity of gefitinibcombined with topotecan in women with recurrent ovarian cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 14 Jan 2020 Planned End Date changed from 1 Sep 2019 to 4 Sep 2020.